SEC Contract Filing

Filing Date: 2017-12-18

Document Content:
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>9
<FILENAME>ex10-4.htm
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXECUTION
VERSION</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTRATION
RIGHTS AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
RIGHTS AGREEMENT</B> (this &ldquo;<B>Agreement</B>&rdquo;), dated as of December 15, 2017, by and among Marrone Bio Innovations,
Inc., a Delaware corporation, with headquarters located at 1540 Drew Avenue, Davis, CA 95618 (the &ldquo;<B>Company</B>&rdquo;),
and the Investors (as hereinafter defined).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Pursuant to the Securities Purchase Agreement by and among the Company and the buyers named therein (the
&ldquo;<B>Buyers</B>&rdquo;) of even date herewith (the &ldquo;<B>Securities Purchase Agreement</B>&rdquo;), the Company has
agreed, upon the terms and subject to the conditions of the Securities Purchase Agreement, to issue and sell to each Buyer
(i) shares (the &ldquo;<B>SPA Shares</B>&rdquo;) of the Company&rsquo;s common stock, par value $0.00001 per share (the
&ldquo;<B>Common Stock</B>&rdquo;) and (ii) warrants (the &ldquo;<B>SPA Warrants</B>&rdquo;), which will be exercisable to
purchase shares of Common Stock (as exercised, collectively, the &ldquo;<B>SPA Warrant Shares</B>&rdquo;) in accordance with
the terms of the SPA Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Pursuant to the Omnibus Amendment No. 4, of even date herewith, by and among the Company and Ivy Science &amp; Technology
Fund, Waddell &amp; Reed Advisors Science &amp; Technology Fund and Ivy VIP Science &amp; Technology, the Company has agreed
to exchange a portion of the outstanding principal amount of the notes described therein for shares of Common Stock (the
&ldquo;<B>Waddell Shares</B>&rdquo;) and warrants (the &ldquo;<B>Waddell Warrants</B>&rdquo;), which shall be exercisable to
purchase shares of Common Stock (as exercised, collectively, the &ldquo;<B>Waddell Warrant Shares</B>&rdquo;) in accordance
with the terms of the Waddell Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
Pursuant to the Sixth Amendment to Loan Agreement, of even date herewith, by and between the Company and Gordon Snyder, an
individual, as administrative agent for the lenders party to that certain Loan Agreement, dated as of October 2, 2012 (as may
be amended from time to time), the Company has agreed to exchange a portion of the outstanding principal amount of the notes
described therein for shares of Common Stock (the &ldquo;<B>Snyder Shares</B>&rdquo; and, collectively with the SPA Shares
and the Waddell Shares, the &ldquo;<B>Common Shares</B>&rdquo;) and warrants (the &ldquo;<B>Snyder Warrants</B>&rdquo;),
which shall be exercisable to purchase shares of Common Stock (as exercised, collectively, the &ldquo;<B>Snyder Warrant
Shares</B>&rdquo;) in accordance with the terms of the Sny